Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IMM-6-415 by Immuneering for Metastatic Colorectal Cancer: Likelihood of Approval
IMM-6-415 is under clinical development by Immuneering and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
IMM-6-415 by Immuneering for Non-Small Cell Lung Cancer: Likelihood of Approval
IMM-6-415 is under clinical development by Immuneering and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
IMM-6-415 by Immuneering for Solid Tumor: Likelihood of Approval
IMM-6-415 is under clinical development by Immuneering and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
IMM-6-415 by Immuneering for Metastatic Pancreatic Cancer: Likelihood of Approval
IMM-6-415 is under clinical development by Immuneering and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase...
IMM-6-415 by Immuneering for Metastatic Melanoma: Likelihood of Approval
IMM-6-415 is under clinical development by Immuneering and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
IMM-6-415 by Immuneering for Gastric Cancer: Likelihood of Approval
IMM-6-415 is under clinical development by Immuneering and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...